Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry
- PMID: 18368063
- DOI: 10.1038/jp.2008.28
Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry
Abstract
Objective: The Palivizumab Outcomes Registry contains data on infants and young children who received palivizumab for the prevention of respiratory syncytial virus (RSV) that causes serious lower respiratory tract illness.
Study design: Prospective observational registry enrolling those who received >or=1 dose of palivizumab during any RSV season (2000 to 2004) at participating US sites.
Result: Of 19 548 subjects enrolled, 40% were born before 32 weeks', 48% between 32 and 35 weeks' and 12% after 35 weeks' gestation. Risk factors included child-care attendance, prematurity, chronic lung disease (CLD) and congenital heart disease (CHD). The RSV hospitalization rate of palivizumab recipients was 1.3%. Gender, gestational age <32 weeks, CLD, CHD, congenital airway abnormality, severe neuromuscular disease, Medicaid insurance and >2 children in household were associated with significantly higher rates. Home-care prophylaxis with palivizumab was associated with reduced hospitalization rates.
Conclusion: Data on the use of palivizumab prophylaxis in primarily high-risk infants confirm low RSV hospitalization rates.
Similar articles
-
Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry.Pediatr Pulmonol. 2003 Jun;35(6):484-9. doi: 10.1002/ppul.10288. Pediatr Pulmonol. 2003. PMID: 12746948
-
Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.Pediatr Infect Dis J. 2003 Feb;22(2 Suppl):S46-54. doi: 10.1097/01.inf.0000053885.34703.84. Pediatr Infect Dis J. 2003. PMID: 12671452
-
Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.Pediatr Infect Dis J. 2003 Sep;22(9):823-7. doi: 10.1097/01.inf.0000086403.50417.7c. Pediatr Infect Dis J. 2003. PMID: 14506376
-
Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?Clin Ther. 2004 Dec;26(12):2130-7. doi: 10.1016/j.clinthera.2004.12.005. Clin Ther. 2004. PMID: 15823776 Review.
-
Preventing RSV bronchiolitis in vulnerable infants: the role of palivizumab.Paediatr Respir Rev. 2009 Sep;10(3):143-7. doi: 10.1016/j.prrv.2009.06.002. Epub 2009 Jul 15. Paediatr Respir Rev. 2009. PMID: 19651385 Review.
Cited by
-
Airway Epithelial Cell Junctions as Targets for Pathogens and Antimicrobial Therapy.Pharmaceutics. 2022 Nov 27;14(12):2619. doi: 10.3390/pharmaceutics14122619. Pharmaceutics. 2022. PMID: 36559113 Free PMC article. Review.
-
Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada.Am J Perinatol. 2022 Nov;39(15):1668-1677. doi: 10.1055/s-0041-1725146. Epub 2021 Mar 3. Am J Perinatol. 2022. PMID: 33657636 Free PMC article.
-
Study protocol: a multicenter, uncontrolled, open-label study of palivizumab in neonates, infants, and preschool children at high risk of severe respiratory syncytial virus infection.BMC Pediatr. 2021 Mar 2;21(1):106. doi: 10.1186/s12887-021-02567-6. BMC Pediatr. 2021. PMID: 33653291 Free PMC article.
-
Acute respiratory infections in hospitalised infants with congenital heart disease.Cardiol Young. 2021 Apr;31(4):547-555. doi: 10.1017/S1047951120004333. Epub 2020 Dec 14. Cardiol Young. 2021. PMID: 33308367 Free PMC article.
-
Overview of Current Therapeutics and Novel Candidates Against Influenza, Respiratory Syncytial Virus, and Middle East Respiratory Syndrome Coronavirus Infections.Front Microbiol. 2019 Jun 19;10:1327. doi: 10.3389/fmicb.2019.01327. eCollection 2019. Front Microbiol. 2019. PMID: 31275265 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical